Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06899074 · ClinicalTrials.gov registry record · NA
Omega-3 Supplementation for Pediatric Migraine
A NA study of Migraine, sponsored by University of North Carolina, Chapel Hill.
- Active
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT06899074: Active NA study of Migraine, sponsored by University of North Carolina, Chapel Hill.
NCT06899074 is a NA study of Migraine that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 58 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06899074, a NA study of Migraine, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the biochemical and clinical effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation in youth suffering from migraine, including its effects on migraine disability, psychological distress, and overall quality of life. This study duration 12 weeks.
Primary Outcome
The Omega-3 Index is defined as the combined percentage of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell membranes, expressed as a percentage of total fatty acids. Possible range: 0-100%. Higher values indicate greater incorporation of omega-3-fatty acids (favorable outcome). This outcome compares the change in omega-3 index levels via finger prick blood test.
Conditions Studied
Interventions
- OTHER Matching Placebo
- DIETARY_SUPPLEMENT Omega 3 Polyunsaturated Fats
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2026-03 |
| Phase | NA |
What the registry record for NCT06899074 still lists
NCT06899074 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Matching Placebo is the first listed.
NCT06899074 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06899074 about?
NCT06899074 is a clinical study titled "Omega-3 Supplementation for Pediatric Migraine". The purpose of the study is to assess the biochemical and clinical effects of omega-3 polyunsaturated fatty acid (PUFA) supplementation in youth suffering from migraine, including its effects on migraine disability, psychological distress, and overall quality of life. This study duration 12 weeks.
What is the current status of trial NCT06899074?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 58 participants. The study started on 2025-04-17. Estimated completion is 2026-03.
What conditions does trial NCT06899074 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06899074?
The interventions under investigation include: Matching Placebo (OTHER), Omega 3 Polyunsaturated Fats (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06899074?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06899074 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06899074's enrollment target sits among peer trials
58 80th of 102 higher than 23 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI